Clinical trial · Observational
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chromogenic in situ hybridization | Genetic | — | UNRESOLVED |
| fluorescent antibody technique | Other | — | UNRESOLVED |
| gene expression analysis | Genetic | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| matrix-assisted laser desorption/ionization time of flight mass spectrometry | Other | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| polymerase chain reaction | Genetic | — |
Design
Arms and outcomes
Arms (4)
- label
- Male, Never-smokers
- description
- Male subjects who smoked less than 100 cigarettes during their lifetime.
- interventionNames
- Genetic: chromogenic in situ hybridization
- Genetic: gene expression analysis
- Genetic: mutation analysis
- Genetic: polymerase chain reaction
- Genetic: polymorphism analysis
- Other: fluorescent antibody technique
- Other: immunohistochemistry staining method
- Other: laboratory biomarker analysis
- Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
- Other: study of socioeconomic and demographic variables
- Procedure: study of high risk factors
- label
- Male, Ever-smokers
- description
- Male subjects who have smoked at least 100 cigarettes during their lifetime.
- interventionNames
- Genetic: chromogenic in situ hybridization
- Genetic: gene expression analysis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed non-small cell lung cancer
* Stage I, II, IIIA, or IIIB (T4 or N3) disease
* No malignant pleural effusion; if pleural fluid is present, 1 of the following criteria must be met:
* Benign pleural fluid
* Pleural fluid is due to prior thoracotomy
* Pleural fluid is deemed too small to safely tap
* No diagnosis by cytology alone
* Newly diagnosed disease
* Must have tumor blocks/slides available and must be willing to provide tissue samples
* Prior smoking history meeting 1 of the following criteria:
* Never smoker, defined as \< 100 cigarettes in lifetime
* Former smoker, defined as no smoking for ≥ 1 year
* Current smoker, defined as all others (closed to accrual as of 7/15/07)
* No pericardial effusions
PATIENT CHARACTERISTICS:
* No other prior malignancy except for 1 of the following:
* Adequately treated basal cell or squamous cell skin cancer
* In situ cervical cancer
* Other cancer for which the patient has been disease free for five years
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy or radiotherapy
* Concurrent participation in therapeutic trials allowedReferences
Publications (0)
Data not yet available